[go: up one dir, main page]

WO2009047826A3 - Pharmaceutical composition comprising sucralphate and mesalazine - Google Patents

Pharmaceutical composition comprising sucralphate and mesalazine Download PDF

Info

Publication number
WO2009047826A3
WO2009047826A3 PCT/IT2008/000639 IT2008000639W WO2009047826A3 WO 2009047826 A3 WO2009047826 A3 WO 2009047826A3 IT 2008000639 W IT2008000639 W IT 2008000639W WO 2009047826 A3 WO2009047826 A3 WO 2009047826A3
Authority
WO
WIPO (PCT)
Prior art keywords
lesions
sucralphate
mesalazine
rectum
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT2008/000639
Other languages
French (fr)
Other versions
WO2009047826A8 (en
WO2009047826A2 (en
Inventor
Domenico Russo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TUTTOFARMACO Srl
Original Assignee
TUTTOFARMACO Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TUTTOFARMACO Srl filed Critical TUTTOFARMACO Srl
Publication of WO2009047826A2 publication Critical patent/WO2009047826A2/en
Publication of WO2009047826A3 publication Critical patent/WO2009047826A3/en
Publication of WO2009047826A8 publication Critical patent/WO2009047826A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a pharmaceutical composition comprising sucralphate and mesalazine, and formulated as a gel, cream, enema, or rectal suppository. The use of this formulation is for the treatment of diseases such as actinic proctitis, diversion proctitis, aphthoid lesions of the rectum caused by avitaminosis or viruses, rhagades, fistulizing lesions, solitary ulcer of the rectum, haemorrhoids, anal itching. Other possible applications relate to the use in the treatment of rectal lesions caused by endoscopic dilatation, lesions of the rectum caused by radiotherapy or chemotherapy.
PCT/IT2008/000639 2007-10-11 2008-10-08 Pharmaceutical composition comprising sucralphate and mesalazine Ceased WO2009047826A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001965A ITMI20071965A1 (en) 2007-10-11 2007-10-11 PHARMACEUTICAL COMPOSITION INCLUDING SUCRALFATE AND MESALAZINE
ITMI2007A001965 2007-10-11

Publications (3)

Publication Number Publication Date
WO2009047826A2 WO2009047826A2 (en) 2009-04-16
WO2009047826A3 true WO2009047826A3 (en) 2009-09-11
WO2009047826A8 WO2009047826A8 (en) 2010-01-28

Family

ID=40313806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2008/000639 Ceased WO2009047826A2 (en) 2007-10-11 2008-10-08 Pharmaceutical composition comprising sucralphate and mesalazine

Country Status (2)

Country Link
IT (1) ITMI20071965A1 (en)
WO (1) WO2009047826A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2449316B1 (en) * 2012-09-19 2015-03-09 Mondejar José Hernandez Physiological solution for internal anal canal hygiene
CN104524300A (en) * 2015-01-08 2015-04-22 李宏 Medicament for improving myocardial ischemia injury caused by chemotherapy and preparation method
CN105343687A (en) * 2015-11-13 2016-02-24 张雯 Traditional Chinese medicine for treating rectitis and colitis and its preparation method
CN108853293B (en) * 2018-09-25 2021-07-23 江西中医药大学 Compound essential oil for treating hemorrhoids and preparation method and use method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004034A1 (en) * 1989-09-15 1991-04-04 Pehrom Pharmaceutical Corporation Topical preparation for treatment of aphthous ulcers and other lesions
WO2002022120A1 (en) * 2000-09-15 2002-03-21 Medical Merchandising, Inc. Pain reliever and method of use
WO2005115075A2 (en) * 2004-05-27 2005-12-08 Antibe Therapeutics Inc. Salt of 4- or 5- aminosalicylic acid
US20070167416A1 (en) * 2006-11-03 2007-07-19 Johnson Lorin K Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004034A1 (en) * 1989-09-15 1991-04-04 Pehrom Pharmaceutical Corporation Topical preparation for treatment of aphthous ulcers and other lesions
WO2002022120A1 (en) * 2000-09-15 2002-03-21 Medical Merchandising, Inc. Pain reliever and method of use
WO2005115075A2 (en) * 2004-05-27 2005-12-08 Antibe Therapeutics Inc. Salt of 4- or 5- aminosalicylic acid
US20070167416A1 (en) * 2006-11-03 2007-07-19 Johnson Lorin K Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANT M: "Treatment of postoperative anorectal structures with suppositories of vitamin E", NEW YORK STATE JOURNAL OF MEDICINE, MEDICAL SOCIETY OF THE STATE OF NEW YORK, US, vol. 53, no. 20, 15 October 1953 (1953-10-15), pages 2376 - 2378, XP008108461, ISSN: 0028-7628 *
CAMPIERI M ET AL: "Sucralfate, 5-aminosalicylic acid and placebo enemas in the treatment of distal ulcerative colitis", EUROPEAN JOURNAL OF GASTROENTEROLOGY HEPATOLOGY, XX, XX, vol. 3, no. 1, 1 January 1991 (1991-01-01), pages 41 - 44, XP008108455, ISSN: 0954-691x *
KASAPIDIS P ET AL: "Dual rectal therapy: A new and effective combined treatment of mild to moderate radiation proctitis", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 114, no. 4 part 2, 15 April 1998 (1998-04-15), pages A21, XP008108508, ISSN: 0016-5085 *
RAO SSC ET AL: "DOES BIOFEEDBACK THERAPY IMPROVE SYMPTOMS AND ANORECTAL FUNCTION IN SOLITARY RECTAL ULCER SYNDROME (SRUS)?", DIGESTIVE DISEASE WEEK ABSTRACTS AND ITINERARY PLANNER, vol. 2003, 2003, & DIGESTIVE DISEASE 2003; FL, ORLANDO, USA; MAY 17-22, 2003, pages Abstract No. W1505, XP008108457 *
SHARARA ET AL: "Solitary rectal ulcer syndrome: endoscopic spectrum and review of the literature", GASTROINTESTINAL ENDOSCOPY, ELSEVIER, NL, vol. 62, no. 5, 1 November 2005 (2005-11-01), pages 755 - 762, XP005120271, ISSN: 0016-5107 *

Also Published As

Publication number Publication date
WO2009047826A8 (en) 2010-01-28
WO2009047826A2 (en) 2009-04-16
ITMI20071965A1 (en) 2009-04-12

Similar Documents

Publication Publication Date Title
Kamat et al. A study on neuroinflammatory marker in brain areas of okadaic acid (ICV) induced memory impaired rats
Gao et al. Genkwanin inhibits proinflammatory mediators mainly through the regulation of miR-101/MKP-1/MAPK pathway in LPS-activated macrophages
Li et al. Anti-inflammatory activity of patchouli alcohol isolated from Pogostemonis Herba in animal models
Ramanan et al. Inhibition of the enzymes in the leukotriene and prostaglandin pathways in inflammation by 3-aryl isocoumarins
IL255752B (en) Compounds, pharmaceutical preparations containing the same uses for the treatment of cardiovascular disease, inflammatory diseases and cancer
WO2009047826A3 (en) Pharmaceutical composition comprising sucralphate and mesalazine
Khloya et al. Synthesis and biological evaluation of pyrazolylthiazole carboxylic acids as potent anti-inflammatory–antimicrobial agents
WO2011113013A3 (en) Methods and compositions for treating viral or virally-induced conditions
PL2444081T3 (en) Composition for the treatment of inflammatory diseases, containing boswellic acid and cannabidiol
NI201200072A (en) METHODS AND COMPOSITIONS TO TREAT CANCER
EA201171350A1 (en) SUBSTITUTED AROMATIC COMPOUNDS AND THEIR PHARMACEUTICAL APPLICATIONS
Macias-Ceja et al. Role of the epithelial barrier in intestinal fibrosis associated with inflammatory bowel disease: relevance of the epithelial-to mesenchymal transition
Zhang et al. Anti-inflammatory effect of chlorogenic acid in Klebsiella pneumoniae-induced pneumonia by inactivating the p38MAPK pathway
CL2013001643A1 (en) Pharmaceutical composition comprising: 1) n - [(2s) -2,3-dihydroxypropyl] -3- (2-fluoro-4-iodoanilino) pyridin-4-carboxamide and 2a) 2-amino-n- [3- [ [3- (2-Chloro-5-methoxyanilin) quinoxalin-2-yl] sulfamoyl] phenyl] -2-methylpropanamide or 2b) 2-amino-8-ethyl-4-methyl-6- (1h-pyrazole-5- il) pyrido [2,3-d] pyrimidin-7-one; its use for the treatment of cancer; a kit
JP2010511597A5 (en)
CN110546150A (en) Pyrazolyl-containing tricyclic derivatives, preparation method and application thereof
EA201171270A1 (en) APPLICATION OF NIFURATEL IN THE TREATMENT OF INFECTIONS CAUSED BY ATOPOBIUM
MY159756A (en) Nitrile derivatives and their pharmaceutical use and compositions
WO2009027077A8 (en) 5-arylalkylidene-2-arylalkyl-thiazol-4-one derivatives as inhibitors of 5-lipoxygenase and uses thereof
CN103012347B (en) Urea enzyme inhibitor flavone hydroxamic acid compounds and preparation methods and uses thereof
CN102697771A (en) New application of alpinetin
PA8661701A1 (en) THIAZOLIDINONES, ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT
DK1846430T3 (en) Hitherto unknown macrolides
EP1968559A4 (en) BOTANICAL ANTI-INFLAMMATORY PRODUCTS FOR THE TREATMENT OF METABOLIC SYNDROME AND DIABETES
EP2184352A4 (en) DOUBLE-STRANDED NUCLEIC ACID MOLECULE, CANCER CELL PROLIFERATION INHIBITOR AND PHARMACEUTICAL AGENT SUITABLE FOR THE PREVENTION OR TREATMENT OF UTERINE CANCER, BREAST CANCER AND BLADDER CANCER

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08837983

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08837983

Country of ref document: EP

Kind code of ref document: A2